According to Zacks, “Clearside Biomedical, Inc. is a biopharmaceutical company is engaged in developing first-in-class drug therapies to treat blinding diseases of the eye using Clearside proprietary suprachoroidal space(TM) microinjector. Its products include CLS-1001 for the treatment of macular edema associated with non-infectious uveitis; CLS-1003 for the treatment of macular edema associated with retinal vein occlusion; and CLS-1002 program for the treatment of wet age-related macular degeneration. Clearside Biomedical, Inc. is headquartered in Alpharetta, Georgia. “
Several other research firms have also recently commented on CLSD. Needham & Company LLC reaffirmed a “hold” rating on shares of Clearside Biomedical in a report on Wednesday, November 11th. ValuEngine cut Clearside Biomedical from a “buy” rating to a “hold” rating in a research note on Tuesday, January 5th. Three equities research analysts have rated the stock with a hold rating and three have issued a buy rating to the company’s stock. The stock currently has a consensus rating of “Buy” and an average price target of $5.75.
Clearside Biomedical (NASDAQ:CLSD) last posted its quarterly earnings results on Sunday, November 15th. The company reported ($0.05) EPS for the quarter, beating the consensus estimate of ($0.12) by $0.07. Clearside Biomedical had a negative return on equity of 153.41% and a negative net margin of 144.47%. The firm had revenue of $3.43 million during the quarter, compared to analysts’ expectations of $0.70 million. On average, equities research analysts anticipate that Clearside Biomedical will post -0.37 EPS for the current fiscal year.
In related news, major shareholder Bradford T. Whitmore bought 350,750 shares of the firm’s stock in a transaction that occurred on Wednesday, January 6th. The stock was purchased at an average cost of $2.85 per share, for a total transaction of $999,637.50. Following the completion of the acquisition, the insider now owns 3,529,845 shares in the company, valued at approximately $10,060,058.25. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, major shareholder Bradford T. Whitmore bought 51,195 shares of the firm’s stock in a transaction that occurred on Thursday, December 24th. The stock was bought at an average price of $1.95 per share, with a total value of $99,830.25. Following the completion of the acquisition, the insider now owns 3,179,095 shares of the company’s stock, valued at approximately $6,199,235.25. The disclosure for this purchase can be found here. Insiders bought 579,845 shares of company stock valued at $1,411,653 over the last ninety days. Insiders own 13.10% of the company’s stock.
A number of large investors have recently added to or reduced their stakes in the stock. Bridgeway Capital Management Inc. boosted its holdings in Clearside Biomedical by 104.4% in the second quarter. Bridgeway Capital Management Inc. now owns 184,000 shares of the company’s stock valued at $346,000 after purchasing an additional 94,000 shares during the period. Jane Street Group LLC boosted its holdings in Clearside Biomedical by 33.8% in the second quarter. Jane Street Group LLC now owns 55,348 shares of the company’s stock valued at $104,000 after purchasing an additional 13,982 shares during the period. Principal Financial Group Inc. purchased a new position in Clearside Biomedical in the second quarter valued at $67,000. Squarepoint Ops LLC purchased a new position in Clearside Biomedical in the third quarter valued at $51,000. Finally, Charles Schwab Investment Management Inc. purchased a new position in Clearside Biomedical in the second quarter valued at $50,000. Hedge funds and other institutional investors own 24.77% of the company’s stock.
About Clearside Biomedical
Clearside Biomedical, Inc, a biopharmaceutical company, develops and delivers treatment that restore and preserve vision for people with serious eye diseases. Its preclinical products include CLS-AX, an axitinib for suprachoroidal injection. It also develops XIPERE, a triamcinolone acetonide suprachoroidal injectable suspension for the treatment of macular edema associated with uveitis, diabetic macular edema, and macular edema associated with retinal vein occlusion.
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Clearside Biomedical Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Clearside Biomedical and related companies with MarketBeat.com's FREE daily email newsletter.